Among the growth-hormone-releasing peptides, tesamorelin is unusual: it is an actual approved medicine with real randomised controlled trial evidence behind a specific, measurable effect on visceral fat. That makes it more grounded than most compounds in this category. But the approval is for a narrow population, the effect has clear limits, and it is not the general-purpose belly-fat drug it sometimes gets presented as. This guide sets out what tesamorelin genuinely does and where the honesty line sits.
The headline: in the population it was studied in, tesamorelin reliably reduces visceral adipose tissue — the deep fat around the organs — but that fat comes back when you stop, and its use outside that population is off-label and far less studied.
What it is
Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH). Like other GHRH analogues, it works upstream: it binds the GHRH receptor on the pituitary and stimulates the gland to release more of the body's own growth hormone in a broadly physiological, pulsatile pattern. That raises downstream IGF-1. The modifications make it more resistant to breakdown than native GHRH, giving it a usable pharmacology as an injected daily drug.
Because it works through the pituitary rather than replacing GH directly, it retains some of the body's feedback control — a meaningful contrast with injecting recombinant HGH.
The real FDA-approved indication
This is the part that gets blurred. Tesamorelin (brand name Egrifta) is FDA-approved for one thing: to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. That is a specific condition in which HIV and some older antiretroviral therapies drove abnormal fat redistribution, including a build-up of deep abdominal fat. It is not approved as a general weight-loss drug, a bodybuilding aid, or a treatment for ordinary belly fat in healthy people. Any use outside HIV lipodystrophy is off-label.
What the trials actually showed
The evidence base here is genuinely better than for most peptides:
- Phase 3 randomised, placebo-controlled trials in patients with HIV-associated lipodystrophy showed tesamorelin produced a clinically meaningful reduction in visceral adipose tissue measured by CT — on the order of roughly 15 percent to 18 percent over about six months, versus little change on placebo.
- The effect was specific to visceral fat. It reduced the deep abdominal fat depot rather than causing broad weight loss, which is why CT-measured visceral fat, not scale weight, was the primary outcome.
- IGF-1 rose, as expected for a GHRH analogue, and had to be monitored.
- The benefit was not permanent. When treatment stopped, visceral fat tended to return, meaning the effect depends on continued use rather than being a one-time reset.
Side effects and monitoring
As a GH-axis drug, its side effects track the axis:
- Injection-site reactions were among the most common complaints.
- Fluid retention, joint pain, and muscle aches — the familiar GH-related effects — occurred, though generally milder than with high-dose recombinant HGH because the mechanism is more physiological.
- Effects on glucose and insulin sensitivity are relevant, since raising GH can impair insulin action; blood glucose is something to watch, especially in anyone with diabetes risk.
- IGF-1 is monitored during treatment, and the drug is not recommended where there is active malignancy, given the general caution around raising GH/IGF-1 signalling.
Where the honesty line is
Tesamorelin's evidence is real but bounded. The trials were in HIV lipodystrophy, not in healthy lifters or people simply wanting a flatter stomach, so extrapolating the exact effect size to those groups is not justified by the data. The fat returns on discontinuation, so it is not a cure so much as an ongoing treatment. And it shares the GH axis's metabolic trade-offs around glucose. It is a legitimate, well-studied tool for a specific problem — not a shortcut for general fat loss, and not free of the growth-hormone caveats that apply to everything in this class.
Legal and sporting status
Tesamorelin is a prescription medicine for its approved indication. In sport it is prohibited at all times under the WADA Prohibited List (class S2, as a GHRH/growth-hormone-releasing factor), so it is bannable for tested athletes regardless of the reason for use.
Bottom line
Tesamorelin is the GH-axis peptide with actual randomised-trial backing: in people with HIV-associated lipodystrophy it reduces deep visceral fat by roughly 15 to 18 percent over six months by stimulating the body's own GH release. That is a real, measured, specific effect — but it is approved only for that population, the fat comes back when you stop, and it carries the usual GH-related fluid, joint, and glucose caveats. Used for its intended purpose it is well grounded; used as a general belly-fat drug it is off-label and beyond what the evidence covers.